16 August 2019

FHI 360

2018

Commitment Progress

As of December 2018, FHI 360 has exceeded its US$3 million financial pledge to FP2020. Since the 2012 London Summit, FHI 360 expended US$3.5 million of its own resources to support the development and introduction of new, high-quality, affordable contraceptives.

 

With these funds and funding from the Bill & Melinda Gates Foundation, our partner Shanghai Dahua Pharmaceutical Co. Ltd. (Dahua) achieved prequalification from the World Health Organization (WHO) in 2017 for its two-rod contraceptive implant, Levoplant — also referred to as Sino-implant (II). In 2018, Dahua announced an additional price reduction to US$6.90 per unit. In addition, DKT International became their global distributor and just over 1 million units were procured globally. By introducing competition into the contraceptive market, the product has also helped reduce the price of contraceptive implants overall.

 

FHI 360’s financial and program commitments to FP2020 are also reflected in our research and development of new contraceptive products, including biodegradable implants, longer-acting injectables, microneedle patches, and alternative copper IUD designs. FHI 360’s own resources are leveraged with funding from USAID, the Gates Foundation, and the National Institute of Child Health and Human Development.

 

FHI 360 is leading the LEAP LNG-IUS initiative, a project to generate evidence to determine if and how expanded access to the levonorgestrel-releasing intrauterine system (LNG-IUS) could increase contraceptive use and continuation rates in sub-Saharan Africa. This Gates-funded project builds on previous FHI 360 research and advocacy to support the introduction of the LNG-IUS into FP2020 countries.

 

FHI 360 continues to contribute towards its policy commitment with research, advocacy, and programming. As part of the consortium leading the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study, FHI 360 is generating crucial data as to whether the use of the injectable DMPA increases risk of HIV relative to other contraceptives. The forthcoming evidence, expected in 2019, will support contraceptive decision-making for women at risk of HIV.

 

We also continue to support the generation of evidence on and advocacy for task-sharing for family planning. FHI 360 led the first randomized controlled trial of self-administration of subcutaneous DMPA (DMPA-SC). Results published in 2018 in Lancet Global Health showed that self-administration significantly increased contraceptive continuation rates. The study also demonstrated that community-based health workers can safely train women to self-inject DMPA-SC. This research was supported by USAID and the Children’s Investment Fund Foundation.

Our research and advocacy also contributed to the recent decision by the Ugandan National Drug Authority to allow private drug shops to administer injectable contraceptives.

 

Support for service delivery, including the scale-up of high-impact practices, the integration of family planning into HIV and maternal and child health services, male engagement, and social and behavioral change communication, is also part of FHI 360’s family planning portfolio. FHI 360 also continues to support the development and implementation of national FP Costed Implementation Plans (CIPs). In the past year, we supported the development of a second CIP for Tanzania, a case study on the CIP experience in Zambia, and new and improved tools within the CIP Resource Kit.

 

2017

Commitment Progress

As of February 2018, FHI 360 has exceeded its US$3 million financial pledge to FP2020. Since the 2012 London Summit, FHI 360 expended $3,039,000 of its own resources to support the development and introduction of new high-quality, affordable contraceptives.
With these funds and funding from the Bill & Melinda Gates Foundation, our partner Shanghai Dahua Pharmaceutical Co. Ltd. (Dahua) achieved prequalification from the World Health Organization (WHO) in 2017 for its two-rod contraceptive implant, Levoplant — also referred to as Sino-implant (II). By introducing competition into the contraceptive market, the product has already helped reduce the price of contraceptive implants overall. WHO prequalification will enable Dahua to bring the product to even more women worldwide.
FHI 360’s financial and program commitments to FP2020 are also reflected in our research on and development of new contraceptive products, including biodegradable implants, longer-acting injectables, microneedle patches, and alternative copper IUD designs. FHI 360’s own resources are leveraged with funding from USAID, the Gates Foundation, and the National Institute of Child Health and Human Development.
FHI 360 is leading the Learning about Expanded Access and Potential of the LNG-IUS initiative, a project to generate evidence to determine if and how expanded access to the LNG-IUS could increase contraceptive use and continuation rates in sub-Saharan Africa. This Bill & Melinda Gates Foundation-funded project builds on previous FHI 360 research and advocacy to support the introduction of the LNG-IUS into FP2020 countries.
FHI 360 continues to contribute towards its policy commitment with research, advocacy, and programming. As part of the consortium leading the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study, FHI 360 is generating crucial data as to whether the use of DMPA increases risk of HIV relative to other contraceptives. The forthcoming evidence, expected in 2019, will support contraceptive decision-making for women at risk of HIV.
We continue to support the generation of evidence on, advocacy for, and programming of task-sharing for family planning. FHI 360 is leading the first randomized control trial of community health worker provision of injectable contraception, with the aim of strengthening the WHO recommendation for this practice. Our research and advocacy also contributed to the recent decision by the Ugandan National Drug Authority to allow private drug shops to administer injectable contraceptives.
FHI 360-led research, published in the Lancet Global Health, showed that self-injection of subcutaneous DMPA is safe, effective, and significantly increases contraceptive continuation rates. This research was supported by USAID and the Children’s Investment Fund Foundation.
Support for service delivery, including the scale-up of high-impact practices, the integration of family planning into HIV and maternal and child health services, and social and behavioral change communication, is also part of FHI 360’s family planning portfolio.
Finally, FHI 360 continues to support the development and implementation of national FP Costed Implementation Plans (CIPs). In the past year, we supported the development of a CIP for Zimbabwe and case studies on the CIP experience in Senegal and Tanzania, while also working with FP2020 country focal points on CIP execution.

2016

As part of their commitment to FP2020 in support of Every Woman Every Child, FHI 360 increases its financial commitment, from an original pledge of US$1 million of its own resources to a renewed pledge of US$3 million. These funds will be spent to support the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options. FHI 360 also renews its commitment to expand the evidence base for family planning programming and the translation of evidence into policy and practice. FHI 360 commits to progressing at least 5 new contraceptive methods through the development pipeline and supporting the introduction of new and affordable IUDs into FP2020 target countries. More information about this commitment can be found here.

2014 – Every Newborn Action Plan

FHI 360, through their Alive & Thrive initiative, commits to improving infant and young child feeding and maternal nutrition through large-scale programs in Asia and Africa. In support of achieving the Every Newborn Action Plan and Every Woman Every Child’s aim to save the lives of 16 million women and children by 2015, FHI 360’s work will include strategic technical assistance to realize high coverage nutrition programs, the creation and adoption of tools to facilitate scale up, and strengthened capacity to deliver comprehensive programs of impact in Ethiopia and Burkina Faso. Additionally, this program will test the feasibility of multiple community-based maternal nutrition interventions in Bangladesh. The program’s estimated value is USD $53 million and is supported by the Bill & Melinda Gates Foundation, with additional funding from the Department of Foreign Affairs, Trade and Development Canada (DFATD), and Irish Aid. Alive & Thrive estimates that the program reached 12 million children under two years of age in its first five years and plans to extend that coverage from now through 2017.

2012—London Family Planning Summit

FHI 360 commits to allocating US $1 million of their resources through 2020 in support of the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options to fill gaps and expand choice for women and girls. FHI 360 will also expand the evidence base for safe and effective family planning and will translate high-quality evidence into policy and practice. FHI 360 plans continue efforts to widen the array of safe, effective, acceptable and affordable contraceptives worldwide.

2011

FHI 360, a global development organization with forty years of research and programmatic experience in the areas of maternal health and family planning in developing countries in Africa, Asia and Latin America, commits to supporting the Global Strategy for Women’s and Children’s Health by including a gender focus in the majority of its US Government proposals, with special emphasis on women and girls. Through the launch of its new proposal design manual and other internal tools, FHI 360 plans to set up a process for measuring the number of proposals with gender-disaggregated data in 2012.

2010

FHI commits through the HAND to HAND Campaign to galvanize the community’s contribution to the Global Strategy and endorse the Coalition’s ambitious new goal of achieving 100 million new users of contraception in low-income countries by 2015. FHI is committed to the quality assurance of contraceptive commodities and its quality assurance program to help ensure the safe use of a wide range of contraceptive methods. Success at meeting this challenge will address the family planning needs of 80% of women in these countries, and reduce by 110,000 the number of women who die giving birth.

Learn More
FHI 360 Logo